Epigenetics: Worth another look?

Nature Reviews Cancer

Volumn 12, Issue 1, 2012, Pages 2-

  McCarthy, Nicola ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APC PROTEIN; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

DNA METHYLATION; EPIGENETICS; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; NOTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 84655165054     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3187     Document Type: Note

References (1)

1. Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non small cell lung cancer. Cancer Discovery 9 Nov 2011 (doi:10.1158/2159-8290.CD-11-0214)